MSCL — Satellos Bioscience Balance Sheet
0.000.00%
- CA$141.04m
- CA$87.46m
- 35
- 22
- 70
- 37
Annual balance sheet for Satellos Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | Interim Report |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.051 | 3.86 | 1.42 | 29.9 | 48.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.353 | 0.418 | 0.192 | 0.44 | 0.435 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.427 | 4.31 | 1.65 | 30.4 | 50.7 |
| Net Property, Plant And Equipment | 0.002 | 0.006 | 0.006 | 0.014 | 0.004 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 0.429 | 9.96 | 4.57 | 33.4 | 50.7 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.02 | 1.67 | 2.09 | 2.74 | 3.58 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.02 | 1.67 | 2.09 | 2.74 | 3.58 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -0.589 | 8.3 | 2.49 | 30.7 | 47.2 |
| Total Liabilities & Shareholders' Equity | 0.429 | 9.96 | 4.57 | 33.4 | 50.7 |
| Total Common Shares Outstanding |